Skip to content

Influence of Acellular Dermal Matrix on Peri-implant Soft Tissue Phenotype and Marginal Bone Loss

Influence of Acellular Dermal Matrix on Peri-implant Soft Tissue Phenotype and Marginal Bone Loss Following Immediate Implant Placement in Anterior Maxilla: A Randomized Controlled Clinical Trial

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07573020
Acronym
ADM
Enrollment
16
Registered
2026-05-07
Start date
2025-04-01
Completion date
2026-03-01
Last updated
2026-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acellular Dermal Matrix, Dental Implant, Immediate Dental Implant Placement, Polytetrafluoroethylene, Soft Tissue Augmentation at Dental Implants

Keywords

Acellular Dermal Matrix, Immediate Dental Implants, Soft-tissue augmentation, Tissue Phenotype, d-PTFE

Brief summary

To evaluate soft tissue augmentation using acellular dermal matrix (ADM) over immediately placed dental implants in anterior maxilla.

Detailed description

This randomized clinical trial was designed to evaluate and compare the efficacy of ADM versus d-PTFE membranes in the preservation of the peri-implant hard and soft tissues in the setting of immediate implant placement on the anterior maxilla.

Interventions

PROCEDUREPolytetrafluoroethylene coverage

The socket with immediately placed dental implant was covered with a d-PTFE membrane cut to fit the surgical site

The socket with immediately placed dental implant was covered with ADM that was inserted into facial and palatal split thickness pouches.

Sponsors

Mansoura University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Patients with non-restorable maxillary anterior tooth/teeth. * Good oral hygiene. * Patients' cooperation and fully capable to comply with the study protocol. * Age ranges from 18 to 45 years. * Free from history of parafunctional habits e.g. clenching and bruxism * Sufficient inter- arch space.

Exclusion criteria

* Any local pathological condition that contraindicates implant placement. * Pregnancy. * Medication that affects bone healing. * Psychological problems. * Patient had undergone radiation therapy to the head and neck area in the past 12 months.

Design outcomes

Primary

MeasureTime frameDescription
Peri-implant soft-tissue phenotypeSix months following implant placementA standardized periodontal probe was used to clinically measure the keratinized mucosal width, supracrestal tissue height, and mucosal thickness. They were measured in millimeters (mm)

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 8, 2026